

## Surveillance of Individuals after Monkeypox Exposure

### A Clinical VACCELERATE EU Standard



Jan H. Grothe, Ullrich Bethé, The National Coordinators of VACCELERATE: Markus Zeitlinger (AT), Pierre Van Damme (BE), Zoi D. Pana (CY), Petr Husa (CZ), Jens Lundgren (DK), Theoklis Zaoutis (GR), Patrick Mallon (IE), Orly Spivak (IL), Evelina Tacconelli (IT), Ligita Jancoriene (LT), Peter W.M. Hermans (NL), Rebecca Cox (NO), Robert Flisiak (PL), Laura Marques (PT), Jordi Ochando (ES), Murat Akova (TR), Jon Salmanton-García, Oliver A. Cornely

### 1. Background

Since May 2022 Europe faces an outbreak of monkeypox (MPX). The World Health Organisation defines three major ways of transmission. Human-to-human transmission may occur during close unprotected contact with a symptomatic carrier. Close contact with appropriate personal protective equipment is considered safe. Transmission may also occur through respiratory droplets during prolonged face-to-face interaction, and from handling contaminated material without protective gear.<sup>1</sup>

### 2. Procedure

Persons at risk of developing MPX should be closely monitored by the public health authorities. Post exposure prophylaxis (PEP) is advised to be administered within 4 days of exposure to prevent disease. Vaccination within 14 days of exposure may still reduce disease severity. The incubation period ranges from 5 to 21 days. During this time, contact persons should be attentive for possible symptoms.<sup>2,3</sup>

Active monitoring by trained professionals can help improve the quality of symptom assessment. The baseline visit is best done in person and should be continued at weekly intervals by phone or video call. The checklist is meant to facilitate this task. As soon as symptoms are detected, immediate self-isolation and notification of appropriate authority is indicated. Anonymized data collected during this period may be retrospectively recorded for study purposes in this online questionnaire.

Please check this website <https://vaccelerate.eu/mpox/> for more information.

First appointment with treating physician=documentation start=Day 0	Date	
First exposure to MPX	Date	
PEP MPX vaccination offered	Y/N	
PEP MPX vaccine administered	Date	

		Visit or call on			
		Day 6-8	Day 13-15	Day 20-22	Day 27-29
Date of the visit or call	Date				
Fever >38.0°C onset	Date				
Lymphadenopathy onset	Date				
Rash onset	Date				
Pustules onset	Date				
Myalgia onset	Date				
Conjunctivitis onset	Date				
Headache onset	Date				
Nausea/vomiting onset	Date				
Sore throat onset	Date				
Cough onset	Date				
MPX disease diagnosed	Date				

### 3. References

1. WHO. Surveillance, case investigation and contact tracing for monkeypox: interim guidance, 24 June 2022.
2. ECDC. Factsheet for health professionals on monkeypox, 2022.
3. ECDC. RAPID RISK ASSESSMENT: Monkeypox multi-country outbreak, 2022.